Bimagrumab

Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013, it was announced that bimagrumab had received a breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by the US Food and Drug Administration.[1]

Bimagrumab
Monoclonal antibody
Type	?
Source	Human
Target	ACVR2B
Clinical data
Other names	BYM338
ATC code	none
Identifiers
CAS Number	1356922-05-8
ChemSpider	none
UNII	N15SW1DIV8
KEGG	D10620^Y
Chemical and physical data
Formula	C₆₃₀₆H₉₇₃₂N₁₆₈₄O₁₉₉₀S₄₆
Molar mass	142451.78 g·mol⁻¹

In 2014, Bimagrumab entered Phase II development, with some research indicating clinical effects.[2] Novartis planned to apply in 2016 for FDA approval to treat sIBM patients with bimagrumab.[3]

In April 2016, Novartis announced that bimagrumab had failed a Phase IIb/III study for sporadic inclusion body myositis.[4]

In January 2021, a new study confirmed that treatment with Bimagrumab is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes.[5]

References

"Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM)". Retrieved 20 August 2013.
Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J, et al. (December 2014). "Treatment of sporadic inclusion body myositis with bimagrumab". Neurology. 83 (24): 2239–46. doi:10.1212/WNL.0000000000001070. PMC 4277670. PMID 25381300.
Novartis: Planned filings 2015 to >=2019. Retrieved 27 May 2015.
Novartis’ ‘breakthrough’ muscle drug bimagrumab flunks a late-stage trial
"Medication shows promise for weight loss in patients with obesity, diabetes". EurekAlert!. Retrieved 2021-01-20.

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone ("-os-", "-s(o)-")

Human ("-osu-")	Burosumab Denosumab
Humanized ("-sozu-")	Blosozumab Romosozumab

Musculoskeletal ("-mul-")

Human ("-mulu-")	Stamulumab^†

Circulatory ("-c(i[r])-")

Human ("-ciru-")	Alirocumab Ascrinvacumab Enoticumab Evinacumab^† Evolocumab Icrucumab Inclacumab Nesvacumab Orticumab Ramucirumab Rinucumab
Mouse ("-ciro-")	Biciromab^‡ Imciromab^‡
Chimeric ("-cixi-")	Abciximab Volociximab
Humanized ("-cizu-")	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Demcizumab Etaracizumab Faricimab^† Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Neurologic ("-ne(u)(r)-")

Human ("-neru-")	Aducanumab^† Erenumab Fasinumab^† Fulranumab Gantenerumab^† Opicinumab
Humanized ("-nezu-"/"-neuzu-")	Bapineuzumab^† Crenezumab^† Eptinezumab Fremanezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Solanezumab Tanezumab^†

Angiogenesis inhibitor ("-anibi-")

Humanized ("-anibizu-")	Ranibizumab

Growth factor ("-gr(o)-")

Human ("-gru-")	Bimagrumab Trevogrumab
Humanized ("-grozu-")	Domagrozumab Landogrozumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Monoclonal antibodies for the immune system

Immune system

Human	Immunosuppression: Abrilumab Adalimumab^# Anifrolumab^† Atorolimumab Avelumab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Golimumab Ianalumab^† Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab^† Sarilumab Sifalimumab Tabalumab Tezepelumab^† Ulocuplumab Varlilumab Immune activation: Ipilimumab Atezolizumab Durvalumab Nivolumab Pembrolizumab Tremelimumab^† Urelumab Other: Bertilimumab Zanolimumab
Mouse	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	Andecaliximab^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	Immunosuppressive: Aselizumab Apolizumab^§ Benralizumab Camrelizumab^† Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Dostarlimab^† Eculizumab Efalizumab^‡ Epratuzumab Erlizumab Etrolizumab^† Fontolizumab Inebilizumab Itolizumab Lampalizumab^† Letolizumab Ligelizumab^† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140^† Quilizumab Ravulizumab Reslizumab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab^† Talizumab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Non-immunosuppressive: Ibalizumab
Chimeric + humanized	Otelixizumab Sutimlimab^†

Interleukin

Human	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab^† Ustekinumab
Humanized	Anrukinzumab Bimekizumab^† Clazakizumab Gevokizumab Ixekizumab Mirikizumab^† Lebrikizumab Olokizumab^† Perakizumab Risankizumab Tildrakizumab
Veterinary	Lokivetmab

Inflammatory lesions

Mouse	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.